Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Dec 05, 2023 5:34pm
64 Views
Post# 35769965

RE:Injector

RE:InjectorYear3000 as usual just enough of vagueness so that you don't really have any precise answers.  Do the mean completing development of the device by the end of 2023 or just sometime in 2023 which by the way is running out of time.  Securing a contract manufacturer I heard this at the AGM in September 2 1/2 months ago so that has not gone anywhere.   My disappointment is in Mainpointe who were supposed to coordinate and finance the device to FDA Approval.  That obviously has not happened.

Instead of hearing something about the Dermal Injector I think what we will hear next is about what they are presntly working on:
Partnering with a large Pharma to market RCH-01
Sell the global rights to RCH-01 to a large Pharma (possibly Shiseido)
Selling the company and all assets to a large Pharma

I certainly hope it is one of the above rather than some vague update on the Dermal Injector targeted to be marketed sometime in late 2024 or beyond.








<< Previous
Bullboard Posts
Next >>